Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Altimmune (ALT) over the last 16 years, with Q3 2025 value amounting to $4.0 million.

  • Altimmune's Change in Account Payables rose 35421.22% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 29189.75%. This contributed to the annual value of -$1.9 million for FY2024, which is 3200.44% up from last year.
  • Latest data reveals that Altimmune reported Change in Account Payables of $4.0 million as of Q3 2025, which was up 35421.22% from -$226000.0 recorded in Q2 2025.
  • Altimmune's Change in Account Payables' 5-year high stood at $4.0 million during Q3 2025, with a 5-year trough of -$1.6 million in Q3 2024.
  • Moreover, its 5-year median value for Change in Account Payables was -$194000.0 (2021), whereas its average is $220631.6.
  • Data for Altimmune's Change in Account Payables shows a peak YoY increase of 87229.78% (in 2021) and a maximum YoY decrease of 30818.99% (in 2021) over the last 5 years.
  • Over the past 5 years, Altimmune's Change in Account Payables (Quarter) stood at $2.0 million in 2021, then soared by 66.91% to $3.4 million in 2022, then tumbled by 128.83% to -$976000.0 in 2023, then grew by 5.53% to -$922000.0 in 2024, then soared by 528.74% to $4.0 million in 2025.
  • Its Change in Account Payables stands at $4.0 million for Q3 2025, versus -$226000.0 for Q2 2025 and $866000.0 for Q1 2025.